Cookie Policy

This site uses cookies to store information on your computer.

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Misago® - Self-expanding peripheral stent

Terumo is in every detail

Misago is a peripheral self-expanding stent system consisting of a rapid exchange delivery catheter and a pre-mounted stent made of nitinol.

Misago is intended for use in the treatment of stenotic or occlusive lesions in iliac or femoro-popliteal arteries to establish and maintain patency.

Characteristics

  • Increased conformability within unique open-cell design1
  • Optimized radial force to reduce thrombosis and neointima hyperplasia1,2
  • Increased flexibility in severe bend situations1
  • Precise deployment with simplified single-operator system3
  • Proven performance in treating patients worldwide with peripheral artery disease (PAD)3,4,5

General Specifications

Stent materialNitinol alloy
Stent strut thickness0.185 mm
Delivery catheter structureRapid exchange with ergonomic grip
Guidewire compatibility0.035" (0.89 mm)
Minimum sheath size6 Fr / 2.0 mm
Usable length of catheter135 cm

Product Illustrations

See the difference

Increased flexibility lowers the potential for stent fracture:1

  • Open-cell structure: The continuous spine-free stent is designed to promote optimal blood flow and eliminate high-strain stress zones that can lead to fracture1
  • In the JP-OSPREY clinical trial, 0% incidence of stent fracture per stent at 12 months post-procedure3
  • Optimized radial force to reduce thrombosis and neointima hyperplasia2

Feel the difference

​Responds to a patient’s natural anatomy with increased conformability6:

  • Responsive in-vitro performance even in severe bend situations.1 In comparison to other self-expanding nitinol stents tested, Misago demonstrated high flexibility and durability in rigorous fatigue-testing simulations.
  • No stent fractures recorded during:
    • 40% compression test that simulated the response during thigh contraction
    • 90° torsion test that simulated the rotation between supine and fetal position
  • More flexible stents may be associated with improved patency7
  • Precision deployment with 100% delivery success3
    • Minimizes jumping, recoil or foreshortening with an easy-to-use thumbwheel system that allows for single operator deployment
    • Enables exact stent placement with the pushability of a triaxial catheter design

Make a difference

​Realize meaningful long-term outcomes in superficial femoral and popliteal arteries.8

Clinically proven results in difficult to treat lesions:

  • In long calcified lesions (> 8 cm)9
    90.3% Primary patency rate at 1 year
  • In popliteal lesions (p1-p3)10
    91.5% Primary patency rate at 1 year

Item Specifications

Stent
diameter ​
Stent length (mm) ​ ​ ​ ​ ​
406080100120150
5 mmSX-VXA0540LNSX-VXA0560LNSX-VXA0580LNSX-VXA05X0LN
6 mmSX-VXA0640LNSX-VXA0660LNSX-VXA0680LNSX-VXA06X0LNSX-VXA06X2LNSX-VXA06X5LN
7 mmSX-VXA0740LNSX-VXA0760LNSX-VXA0780LNSX-VXA07X0LNSX-VXA07X2LNSX-VXA07X5LN
8 mmSX-VXA0840LNSX-VXA0860LNSX-VXA0880LNSX-VXA08X0LN
9 mmSX-VXA0940LNSX-VXA0960LN
10 mmSX-VXA1040LNSX-VXA1060LN

 Please quote above item reference codes when placing an order

 

 

 

 

Comparison of Second-Generation Stents for Application in the Superficial Femoral Artery: An In Vitro Evalution Focusing on Stent Designhttp://www.terumo-europe.com/en-emea/clinical-program/Clinical Data/Comparison of Second-Generation Stents for Application in the Superficial Femoral Artery.pdfComparison of Second-Generation Stents for Application in the Superficial Femoral Artery: An In Vitro Evalution Focusing on Stent Design30/11/2010 23:00:00{E7C8680A-8208-4B36-A279-4AA5C10ACE0B}HayabusaArticleDocument5add21c9-7e01-415f-a533-57956d0e06e2
MISAGO 1: first-in-man clinical trial with Misago nitinol stenthttp://www.terumo-europe.com/en-emea/clinical-program/Clinical Data/MISAGO 1 first-in-man clinical trial with Misago nitinol stent.pdfMISAGO 1: first-in-man clinical trial with Misago nitinol stent30/04/2010 22:00:00{CA3B0011-BE3E-4ADE-9313-FF221CDB6734}HayabusaArticleDocument5add21c9-7e01-415f-a533-57956d0e06e2

 

 

 

 

See Also

References

1 Müller-Hülsbeck S, Schäfer PJ, Charalambous N, et al. Comparison of Second-Generation Stents for Application in the Superficial Femoral Artery: An In Vitro Evaluation Focusing on Stent Design. J Endovasc Ther. 2010;17(6):767-776.
2 Deloose K, et al. TVR Reduction in the SFA. EVTODAY. October, 2014;44-47.
3 Presented by Dr Yokoi at TCT 2014.
4 Presented by Dr Ruef at CIRSE 2014.
5 Presented by Dr Müller-Hülsbeck at CIRSE 2014.
6 Compared to six other stents with regard to the appearance of fracture. Müller-Hülsbeck S, Schäfer PJ, Charalambous N, et al. Comparison of Second-Generation Stents for Application in the Superficial Femoral Artery: An In Vitro Evaluation Focusing on Stent Design. J Endovasc Ther. 2010;17(6):767-776.
7 Smouse, R. Achieving Long Term SFA Treatment Success: Stent Design or Patient Selection. International Symposium on Endovascular Therapy, January 2014.
8 I. Kralj et al. Vasa, 2012; 42:313.
9 Results from e-Misago registry - n = 434.
10 Results from e-Misago registry - n = 329.

Did you not find the product you were looking for ?